For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
AnaptysBio Inc (NASDAQ: ANAB) closed the day trading at $24.55 down -1.72% from the previous closing price of $24.98. In other words, the price has decreased by -$1.72 from its previous closing price. On the day, 0.51 million shares were traded. ANAB stock price reached its highest trading level at $25.135 during the session, while it also had its lowest trading level at $24.39.
Ratios:
For a better understanding of ANAB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.25 and its Current Ratio is at 8.25. In the meantime, Its Debt-to-Equity ratio is 10.17 whereas as Long-Term Debt/Eq ratio is at 10.11.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $25.
H.C. Wainwright Downgraded its Buy to Neutral on December 11, 2024, whereas the target price for the stock was revised from $52 to $19.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 02 ’25 when RENTON HOLLINGS sold 20,925 shares for $23.57 per share. The transaction valued at 493,191 led to the insider holds 4,965 shares of the business.
HOLLINGS C RENTON bought 20,925 shares of ANAB for $493,190 on Jul 02 ’25. On Jun 18 ’25, another insider, FENTON DENNIS M, who serves as the Director of the company, sold 3,015 shares for $23.97 each. As a result, the insider received 72,270 and left with 4,965 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANAB now has a Market Capitalization of 721291264 and an Enterprise Value of 727312192. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.45 while its Price-to-Book (P/B) ratio in mrq is 21.93. Its current Enterprise Value per Revenue stands at 6.501 whereas that against EBITDA is -7.295.
Stock Price History:
The Beta on a monthly basis for ANAB is -0.19, which has changed by -0.25061053 over the last 52 weeks, in comparison to a change of 0.18569505 over the same period for the S&P500. Over the past 52 weeks, ANAB has reached a high of $41.31, while it has fallen to a 52-week low of $12.21. The 50-Day Moving Average of the stock is 2.78%, while the 200-Day Moving Average is calculated to be 18.42%.
Shares Statistics:
Over the past 3-months, ANAB traded about 582.80K shares per day on average, while over the past 10 days, ANAB traded about 512630 shares per day. A total of 30.39M shares are outstanding, with a floating share count of 26.44M. Insiders hold about 10.01% of the company’s shares, while institutions hold 128.18% stake in the company. Shares short for ANAB as of 1752537600 were 9380774 with a Short Ratio of 16.10, compared to 1749772800 on 9153626. Therefore, it implies a Short% of Shares Outstanding of 9380774 and a Short% of Float of 57.620000000000005.
Earnings Estimates
The current rating of AnaptysBio Inc (ANAB) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.57, with high estimates of -$1.23 and low estimates of -$1.86.
Analysts are recommending an EPS of between -$3.61 and -$7.02 for the fiscal current year, implying an average EPS of -$5.54. EPS for the following year is -$5.1, with 8.0 analysts recommending between -$2.64 and -$6.9.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for ANAB’s current fiscal year. The highest revenue estimate was $216.9M, while the lowest revenue estimate was $27.77M, resulting in an average revenue estimate of $79.43M. In the same quarter a year ago, actual revenue was $91.28M
